NeuroPace (NPCE) Stock Forecast & Price Target

Compare

132 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NPCE Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

NeuroPace

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NPCE Stock 12 Month Forecast

Average Price Target

$18.00

▲(39.10% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $18.00 with a high forecast of $20.00 and a low forecast of $16.00. The average price target represents a 39.10% change from the last price of $12.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","14":"$14","21":"$21","10.5":"$10.5","17.5":"$17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,10.5,14,17.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.65,15.984615384615385,16.31923076923077,16.653846153846153,16.98846153846154,17.323076923076922,17.657692307692308,17.99230769230769,18.326923076923077,18.661538461538463,18.996153846153845,19.33076923076923,19.665384615384617,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.65,15.830769230769231,16.01153846153846,16.192307692307693,16.373076923076923,16.553846153846155,16.734615384615385,16.915384615384614,17.096153846153847,17.276923076923076,17.45769230769231,17.638461538461538,17.81923076923077,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.65,15.676923076923078,15.703846153846154,15.730769230769232,15.757692307692308,15.784615384615385,15.811538461538461,15.838461538461539,15.865384615384615,15.892307692307693,15.919230769230769,15.946153846153846,15.973076923076922,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$18.00

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rohin K Patel

J.P. Morgan

$18→$20

Buy

54.56%

Upside

Reiterated

12/10/25

NeuroPace price target raised to $20 from $18 at JPMorganNeuroPace price target raised to $20 from $18 at JPMorgan

Priya Sachdeva

UBS

$18

Buy

39.10%

Upside

Reiterated

12/09/25

UBS Keeps Their Buy Rating on NeuroPace (NPCE)

Yi Chen

H.C. Wainwright

$18

Buy

39.10%

Upside

Reiterated

12/09/25

Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration

Frank Takkinen

Lake Street

$20

Buy

54.56%

Upside

Reiterated

12/08/25

Analysts Offer Insights on Healthcare Companies: NeuroPace (NASDAQ: NPCE) and Evaxion Biotech (NASDAQ: EVAX)

Ross Osborn

Cantor Fitzgerald

$16

Buy

23.65%

Upside

Reiterated

11/05/25

Cantor Fitzgerald Remains a Buy on NeuroPace (NPCE)We reiterate our Overweight rating and 12‐month price target of $16 on NeuroPace (NPCE) following the strong 3Q25 operating results.

Michael Polark

Wolfe Research

$15→$13

Buy

0.46%

Upside

Reiterated

08/14/25

Wolfe Research Reaffirms Their Buy Rating on NeuroPace (NPCE)Wolfe Research analyst Mike Polark lowered the price target on NeuroPace Inc (NASDAQ: NPCE) to $13.00 (from $15.00) while maintaining a Outperform rating.

Mike Kratky

Leerink Partners

$17→$18

Buy

39.10%

Upside

Reiterated

08/13/25

Leerink Partners Reaffirms Their Buy Rating on NeuroPace (NPCE)We are reiterating our Outperform rating and moving our PT to $18 (from $17) following improved revenue guidance and conservative gross margin outlook.

Vik Chopra

Wells Fargo

$17→$15

Buy

15.92%

Upside

Reiterated

08/13/25

Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE)NPCE (Overweight) Q2 Outperformance Drives Guidance Raise; Mgmt Confirms NAUTILUS PMA Supplement Submission in 2H

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rohin K Patel

J.P. Morgan

$18→$20

Buy

54.56%

Upside

Reiterated

12/10/25

NeuroPace price target raised to $20 from $18 at JPMorganNeuroPace price target raised to $20 from $18 at JPMorgan

Priya Sachdeva

UBS

$18

Buy

39.10%

Upside

Reiterated

12/09/25

UBS Keeps Their Buy Rating on NeuroPace (NPCE)

Yi Chen

H.C. Wainwright

$18

Buy

39.10%

Upside

Reiterated

12/09/25

Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration

Frank Takkinen

Lake Street

$20

Buy

54.56%

Upside

Reiterated

12/08/25

Analysts Offer Insights on Healthcare Companies: NeuroPace (NASDAQ: NPCE) and Evaxion Biotech (NASDAQ: EVAX)

Ross Osborn

Cantor Fitzgerald

$16

Buy

23.65%

Upside

Reiterated

11/05/25

Cantor Fitzgerald Remains a Buy on NeuroPace (NPCE)We reiterate our Overweight rating and 12‐month price target of $16 on NeuroPace (NPCE) following the strong 3Q25 operating results.

Michael Polark

Wolfe Research

$15→$13

Buy

0.46%

Upside

Reiterated

08/14/25

Mike Kratky

Leerink Partners

$17→$18

Buy

39.10%

Upside

Reiterated

08/13/25

Vik Chopra

Wells Fargo

$17→$15

Buy

15.92%

Upside

Reiterated

08/13/25

Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE)NPCE (Overweight) Q2 Outperformance Drives Guidance Raise; Mgmt Confirms NAUTILUS PMA Supplement Submission in 2H

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeuroPace

1 Month

xxx

Success Rate

18/26 ratings generated profit

Average Return

+7.99%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +7.99% per trade.

3 Months

xxx

Success Rate

17/26 ratings generated profit

Average Return

+24.95%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +24.95% per trade.

1 Year

Frank TakkinenLake Street

Success Rate

22/26 ratings generated profit

Average Return

+53.51%

reiterated a buy rating 5 days ago

Copying Frank Takkinen's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +53.51% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+50.78%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +50.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NPCE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NPCE has received 9 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. NPCE average Analyst price target in the past 3 months is 18.00.

Each month's total comprises the sum of three months' worth of ratings.

NPCE Financial Forecast

NPCE Earnings Forecast

Next quarter’s earnings estimate for NPCE is -$0.18 with a range of -$0.22 to -$0.14. The previous quarter’s EPS was -$0.11. NPCE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NPCE has Performed in-line its overall industry.

NPCE Sales Forecast

Next quarter’s sales forecast for NPCE is $24.39M with a range of $23.60M to $24.64M. The previous quarter’s sales results were $27.35M. NPCE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NPCE has Performed in-line its overall industry.

NPCE Stock Forecast FAQ

What is NPCE’s average 12-month price target, according to analysts?

Based on analyst ratings, Neuropace, Inc.’s 12-month average price target is 18.00.

What is NPCE’s upside potential, based on the analysts’ average price target?

Neuropace, Inc. has 39.10% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NPCE a Buy, Sell or Hold?

Neuropace, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Neuropace, Inc.’s price target?

The average price target for Neuropace, Inc. is 18.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 39.10% Increase from the current price of $12.94.

What do analysts say about Neuropace, Inc.?

Neuropace, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of NPCE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

NeuroPace (NPCE) Stock Forecast & Price Target

NPCE Analyst Ratings

NPCE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NeuroPace

NPCE Analyst Recommendation Trends

NPCE Financial Forecast

NPCE Earnings Forecast

NPCE Sales Forecast

NPCE Stock Forecast FAQ

Detailed List of Analyst Forecasts